vs

Side-by-side financial comparison of Cushman & Wakefield Ltd. (CWK) and TENET HEALTHCARE CORP (THC). Click either name above to swap in a different company.

TENET HEALTHCARE CORP is the larger business by last-quarter revenue ($5.5B vs $2.9B, roughly 1.9× Cushman & Wakefield Ltd.). TENET HEALTHCARE CORP runs the higher net margin — 11.7% vs -0.8%, a 12.4% gap on every dollar of revenue. On growth, Cushman & Wakefield Ltd. posted the faster year-over-year revenue change (10.8% vs 9.0%). TENET HEALTHCARE CORP produced more free cash flow last quarter ($367.0M vs $234.3M). Over the past eight quarters, Cushman & Wakefield Ltd.'s revenue compounded faster (15.5% CAGR vs 1.5%).

Cushman & Wakefield Inc. is an American global commercial real estate and property management services firm. The company's corporate headquarters is located in Chicago, Illinois. It is named after co-founders J. Clydesdale Cushman and Bernard Wakefield.

Tenet Healthcare Corporation is an American for-profit multinational healthcare services company based in Dallas. Through its brands, subsidiaries, joint ventures, and partnerships including United Surgical Partners International (USPI), the company operates 65 hospitals and over 450 healthcare facilities. Tenet also runs Conifer Health Solutions, which provides healthcare support services to health systems and other clients.

CWK vs THC — Head-to-Head

Bigger by revenue
THC
THC
1.9× larger
THC
$5.5B
$2.9B
CWK
Growing faster (revenue YoY)
CWK
CWK
+1.8% gap
CWK
10.8%
9.0%
THC
Higher net margin
THC
THC
12.4% more per $
THC
11.7%
-0.8%
CWK
More free cash flow
THC
THC
$132.7M more FCF
THC
$367.0M
$234.3M
CWK
Faster 2-yr revenue CAGR
CWK
CWK
Annualised
CWK
15.5%
1.5%
THC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CWK
CWK
THC
THC
Revenue
$2.9B
$5.5B
Net Profit
$-22.4M
$644.0M
Gross Margin
Operating Margin
6.1%
15.4%
Net Margin
-0.8%
11.7%
Revenue YoY
10.8%
9.0%
Net Profit YoY
-119.8%
12.6%
EPS (diluted)
$-0.10
$4.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CWK
CWK
THC
THC
Q4 25
$2.9B
$5.5B
Q3 25
$2.6B
$5.3B
Q2 25
$2.5B
$5.3B
Q1 25
$2.3B
$5.2B
Q4 24
$2.6B
$5.1B
Q3 24
$2.3B
$5.1B
Q2 24
$2.3B
$5.1B
Q1 24
$2.2B
$5.4B
Net Profit
CWK
CWK
THC
THC
Q4 25
$-22.4M
$644.0M
Q3 25
$51.4M
$579.0M
Q2 25
$57.3M
$522.0M
Q1 25
$1.9M
$622.0M
Q4 24
$112.9M
$572.0M
Q3 24
$33.7M
$681.0M
Q2 24
$13.5M
$477.0M
Q1 24
$-28.8M
$2.3B
Operating Margin
CWK
CWK
THC
THC
Q4 25
6.1%
15.4%
Q3 25
4.1%
16.8%
Q2 25
4.9%
15.6%
Q1 25
2.0%
18.1%
Q4 24
6.6%
16.2%
Q3 24
3.2%
21.3%
Q2 24
3.1%
14.9%
Q1 24
0.9%
61.2%
Net Margin
CWK
CWK
THC
THC
Q4 25
-0.8%
11.7%
Q3 25
2.0%
10.9%
Q2 25
2.3%
9.9%
Q1 25
0.1%
11.9%
Q4 24
4.3%
11.3%
Q3 24
1.4%
13.3%
Q2 24
0.6%
9.3%
Q1 24
-1.3%
43.5%
EPS (diluted)
CWK
CWK
THC
THC
Q4 25
$-0.10
$4.22
Q3 25
$0.22
$3.86
Q2 25
$0.25
$3.14
Q1 25
$0.01
$4.27
Q4 24
$0.49
$3.79
Q3 24
$0.14
$4.89
Q2 24
$0.06
$2.64
Q1 24
$-0.13
$21.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CWK
CWK
THC
THC
Cash + ST InvestmentsLiquidity on hand
$784.2M
$2.9B
Total DebtLower is stronger
$2.7B
$13.1B
Stockholders' EquityBook value
$2.0B
$4.2B
Total Assets
$7.7B
$29.7B
Debt / EquityLower = less leverage
1.40×
3.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CWK
CWK
THC
THC
Q4 25
$784.2M
$2.9B
Q3 25
$634.4M
$3.0B
Q2 25
$618.2M
$2.6B
Q1 25
$623.2M
$3.0B
Q4 24
$793.3M
$3.0B
Q3 24
$775.4M
$4.1B
Q2 24
$567.3M
$2.9B
Q1 24
$553.5M
$2.5B
Total Debt
CWK
CWK
THC
THC
Q4 25
$2.7B
$13.1B
Q3 25
$2.8B
$13.1B
Q2 25
$3.0B
$13.1B
Q1 25
$3.0B
$13.1B
Q4 24
$3.0B
$13.1B
Q3 24
$3.1B
$12.8B
Q2 24
$3.1B
$12.8B
Q1 24
$3.2B
$12.8B
Stockholders' Equity
CWK
CWK
THC
THC
Q4 25
$2.0B
$4.2B
Q3 25
$2.0B
$4.0B
Q2 25
$1.9B
$3.7B
Q1 25
$1.8B
$4.2B
Q4 24
$1.8B
$4.2B
Q3 24
$1.7B
$3.8B
Q2 24
$1.6B
$3.5B
Q1 24
$1.6B
$3.5B
Total Assets
CWK
CWK
THC
THC
Q4 25
$7.7B
$29.7B
Q3 25
$7.7B
$29.4B
Q2 25
$7.6B
$28.7B
Q1 25
$7.4B
$29.2B
Q4 24
$7.5B
$28.9B
Q3 24
$7.5B
$29.4B
Q2 24
$7.3B
$29.3B
Q1 24
$7.5B
$28.9B
Debt / Equity
CWK
CWK
THC
THC
Q4 25
1.40×
3.10×
Q3 25
1.45×
3.26×
Q2 25
1.57×
3.49×
Q1 25
1.70×
3.13×
Q4 24
1.73×
3.14×
Q3 24
1.81×
3.33×
Q2 24
1.91×
3.67×
Q1 24
1.96×
3.70×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CWK
CWK
THC
THC
Operating Cash FlowLast quarter
$257.3M
$731.0M
Free Cash FlowOCF − Capex
$234.3M
$367.0M
FCF MarginFCF / Revenue
8.0%
6.6%
Capex IntensityCapex / Revenue
0.8%
6.6%
Cash ConversionOCF / Net Profit
1.14×
TTM Free Cash FlowTrailing 4 quarters
$293.0M
$2.5B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CWK
CWK
THC
THC
Q4 25
$257.3M
$731.0M
Q3 25
$235.5M
$1.1B
Q2 25
$9.6M
$936.0M
Q1 25
$-162.0M
$815.0M
Q4 24
$115.2M
$-331.0M
Q3 24
$196.1M
$1.0B
Q2 24
$21.8M
$747.0M
Q1 24
$-125.1M
$586.0M
Free Cash Flow
CWK
CWK
THC
THC
Q4 25
$234.3M
$367.0M
Q3 25
$225.0M
$778.0M
Q2 25
$300.0K
$743.0M
Q1 25
$-166.6M
$642.0M
Q4 24
$105.9M
$-661.0M
Q3 24
$186.7M
$829.0M
Q2 24
$10.0M
$602.0M
Q1 24
$-135.6M
$346.0M
FCF Margin
CWK
CWK
THC
THC
Q4 25
8.0%
6.6%
Q3 25
8.6%
14.7%
Q2 25
0.0%
14.1%
Q1 25
-7.3%
12.3%
Q4 24
4.0%
-13.0%
Q3 24
8.0%
16.2%
Q2 24
0.4%
11.8%
Q1 24
-6.2%
6.4%
Capex Intensity
CWK
CWK
THC
THC
Q4 25
0.8%
6.6%
Q3 25
0.4%
5.3%
Q2 25
0.4%
3.7%
Q1 25
0.2%
3.3%
Q4 24
0.4%
6.5%
Q3 24
0.4%
4.2%
Q2 24
0.5%
2.8%
Q1 24
0.5%
4.5%
Cash Conversion
CWK
CWK
THC
THC
Q4 25
1.14×
Q3 25
4.58×
1.83×
Q2 25
0.17×
1.79×
Q1 25
-85.26×
1.31×
Q4 24
1.02×
-0.58×
Q3 24
5.82×
1.53×
Q2 24
1.61×
1.57×
Q1 24
0.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CWK
CWK

Equity Method Investment Nonconsolidated Investee Or Group Of Investees$1.8B61%
Other$1.1B39%

THC
THC

Other$2.9B52%
Health Care Patient Service$1.4B25%
Equity Method Investment Nonconsolidated Investee Or Group Of Investees$1.2B22%
Health Care Other Sources$56.0M1%

Related Comparisons